These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18713565)

  • 1. Spotlight on anti-CD20.
    Waubant E
    Int MS J; 2008 Mar; 15(1):19-25. PubMed ID: 18713565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
    Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.
    Cross AH; Stark JL; Lauber J; Ramsbottom MJ; Lyons JA
    J Neuroimmunol; 2006 Nov; 180(1-2):63-70. PubMed ID: 16904756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
    Gasperini C; Haggiag S; Ruggieri S
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapies for multiple sclerosis targeting B cells.
    Milo R
    Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells?
    Agahozo MC; Peferoen L; Baker D; Amor S
    Mult Scler Relat Disord; 2016 Sep; 9():110-7. PubMed ID: 27645355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell-directed therapies in multiple sclerosis.
    Gasperi C; Stüve O; Hemmer B
    Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging monoclonal antibody therapies for multiple sclerosis.
    Cree B
    Neurologist; 2006 Jul; 12(4):171-8. PubMed ID: 16832236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
    de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
    Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of anti-CD20 "what do B-cells do?".
    Eisenberg R; Looney RJ
    Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
    Treon SP; Anderson KC
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):79-85. PubMed ID: 11226004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
    Taupin P
    Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab: an insider's historical perspective.
    Grillo-López AJ
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):9-16. PubMed ID: 11226006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
    Chen Z; Freedman MS
    Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 monoclonal antibodies: beyond B-cells.
    Avivi I; Stroopinsky D; Katz T
    Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data.
    Hawker K
    Curr Opin Neurol; 2008 Apr; 21 Suppl 1():S19-25. PubMed ID: 18388796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.